Edesa Biotech Inc (EDSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edesa Biotech Inc (EDSA) has a cash flow conversion efficiency ratio of -0.201x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.05 Million) by net assets ($10.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Edesa Biotech Inc's balance sheet to measure how much of total assets are equity-financed.
Edesa Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Edesa Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Edesa Biotech Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Edesa Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edesa Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Il Sung Const
KO:013360
|
-0.199x |
|
NextBoat Inc.
NYSE MKT:NXB
|
-1.990x |
|
Phosco Ltd
AU:PHO
|
0.440x |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
0.070x |
|
Carnival Industrial Corp
TW:1417
|
0.035x |
|
Rama Phosphates Limited
NSE:RAMAPHO
|
0.011x |
|
Cenit Co. Ltd
KQ:037760
|
-0.013x |
|
FarGlory Hotel Co Ltd
TW:2712
|
0.038x |
Annual Cash Flow Conversion Efficiency for Edesa Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Edesa Biotech Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Edesa Biotech Inc (EDSA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $12.45 Million | $-7.32 Million | -0.588x | +76.18% |
| 2024-09-30 | $1.98 Million | $-4.89 Million | -2.468x | -162.17% |
| 2023-09-30 | $7.05 Million | $-6.64 Million | -0.942x | +27.99% |
| 2022-09-30 | $9.39 Million | $-12.28 Million | -1.308x | -24.95% |
| 2021-09-30 | $13.06 Million | $-13.66 Million | -1.046x | -39.16% |
| 2020-09-30 | $6.63 Million | $-4.99 Million | -0.752x | +18.44% |
| 2019-09-30 | $5.26 Million | $-4.85 Million | -0.922x | -125.45% |
| 2018-09-30 | $11.29 Million | $-4.62 Million | -0.409x | +35.62% |
| 2017-09-30 | $7.40 Million | $-4.70 Million | -0.635x | -73.60% |
| 2016-09-30 | $12.31 Million | $-4.51 Million | -0.366x | +33.62% |
| 2015-09-30 | $8.01 Million | $-4.41 Million | -0.551x | +0.52% |
| 2014-09-30 | $7.70 Million | $-4.27 Million | -0.554x | -159.51% |
| 2013-09-30 | $-3.14 Million | $-2.92 Million | 0.931x | +120.08% |
| 2012-09-30 | $851.61K | $-3.95 Million | -4.636x | -713.47% |
| 2011-09-30 | $4.59 Million | $-2.62 Million | -0.570x | -92.42% |
| 2010-09-30 | $2.47 Million | $-732.23K | -0.296x | -281.29% |
| 2009-09-30 | $484.95K | $-37.67K | -0.078x | -- |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more